|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0028621,
umls-concept:C0030705,
umls-concept:C0033607,
umls-concept:C0035379,
umls-concept:C0040808,
umls-concept:C0085405,
umls-concept:C0596545,
umls-concept:C1456409,
umls-concept:C1667052,
umls-concept:C1704419,
umls-concept:C1871526
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-3-17
|
|
pubmed:abstractText |
We prospectively evaluated 28 triple-class experienced HIV-1-infected patients harbouring R5 virus, who received maraviroc, raltegravir and etravirine. By on-treatment analysis, 26 (92%) had less than 50 copies HIV-RNA/ml at week 48. The median (interquartile range) 48-week increase in CD4 cell counts was 267 (136-355) cells/microl. Three serious adverse events occurred: one recurrence of mycobacterial spondylodiscitis, one anal cancer, one Hodgkin lymphoma. Although long-term safety needs further study, this protease inhibitor and nucleoside analogue-sparing regimen showed sustained efficacy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1473-5571
|
|
pubmed:author |
pubmed-author:BigoloniAlbaA,
pubmed-author:CanducciFilippoF,
pubmed-author:CastagnaAntonellaA,
pubmed-author:GalliLauraL,
pubmed-author:GianottiNicolaN,
pubmed-author:LazzarinAdrianoA,
pubmed-author:NozzaSilviaS,
pubmed-author:SalpietroStefaniaS,
pubmed-author:SoriaAlessandroA,
pubmed-author:TambussiGiuseppeG,
pubmed-author:TorreLiviana DellaLD,
pubmed-author:ViscoFrancescaF
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
27
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
924-8
|
|
pubmed:meshHeading |
pubmed-meshheading:20154578-Adult,
pubmed-meshheading:20154578-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:20154578-Cyclohexanes,
pubmed-meshheading:20154578-Drug Interactions,
pubmed-meshheading:20154578-Female,
pubmed-meshheading:20154578-HIV Infections,
pubmed-meshheading:20154578-HIV Protease Inhibitors,
pubmed-meshheading:20154578-HIV-1,
pubmed-meshheading:20154578-Humans,
pubmed-meshheading:20154578-Male,
pubmed-meshheading:20154578-Middle Aged,
pubmed-meshheading:20154578-Pyridazines,
pubmed-meshheading:20154578-Reverse Transcriptase Inhibitors,
pubmed-meshheading:20154578-Salvage Therapy,
pubmed-meshheading:20154578-Triazoles,
pubmed-meshheading:20154578-Viral Load
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.
|
|
pubmed:affiliation |
Department of Infectious Diseases, San Raffaele Scientific Institute, Italy. silvia.nozza@hsr.it
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.
|
